CONTENT HUB
Latest news
Here, you will find announcements, advancements in synthetic DNA technology, and insights into our contributions to the fields of vaccines, gene therapy, cell therapy and gene editing
4basebio receives MHRA GMP licence for manufacture and supply of synthetic DNA
02 APR 2025
Press release: MHRA GMP license for 4basebio
4basebio PLC Announces £40.0 million Equity Issuance and £29.4 million Secondary Sale
29 JUL 2024
4basebio PLC Announces £40.0 million Equity Issuance and £29.4 million Secondary Sale
4basebio announces the supply of its opDNA® DNA products into Tier 1 Pharma client’s vaccine program
10 APR 2024
Press release: Supply of opDNA® DNA products into Tier 1 Pharma client’s vaccine program
4basebio announces key milestone with its client progressing into Phase I clinical trials of an mRNA vaccine manufactured from 4basebio’s opDNA®
21 MAR 2024
Press Release: Client progressing into Phase I clinical trials of an mRNA vaccine manufactured from 4basebio’s opDNA®
4basebio awarded tender to deliver research and GMP-grade synthetic DNA in CPI’s tender process for supplying its RNA Centre of Excellence
1 MAR 2024
Press Release: Tender too deliver research and GMP-grade synthetic DNA in CPI’s tender process
4basebio receives grant to advance its synthetic DNA platform and Hermes® nanoparticle platform for the development of thermostable nucleic acid vaccines
1 AUG 2023
Press Release: Grant to advance synthetic DNA and Hermes® nanoparticle platform
4basebio and Neomatrix announce clinical material supply agreement to develop personalised cancer therapy utilising 4basebio’s proprietary hpDNA
25 MAY 2023
Press Release: 4basebio and Neomatrix announce clinical material supply agreement
Final Results, Notice of AGM and Related Party Transaction
11 MAY 2023
Press Release: Final results for financial year ended 31 December 2022
Signing of new lease and expansion of manufacturing capacity
3 APR 2023
Press Release: 4BB is relocating its manufacturing and quality assurance teams to new premises adjacent to its existing clean room facilities